Article

Current Neurology and Neuroscience Reports

, Volume 3, Issue 3, pp 223-228

Oligodendrogliomas: An update on basic and clinical research

  • Marc SansonAffiliated withInserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriére
  • , Lucinda Aguirre-CruzAffiliated withInserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriére
  • , Stéphanie Cartalat-CarelAffiliated withInserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriére
  • , Khe Hoang-XuanAffiliated withInserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriére

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Oligodendrogliomas have been the focus of considerable interest over the past decade, ever since they were recognized as chemosensitive tumors. They were once believed to represent less than 5% of gliomas, but by using expanded criteria, they may well represent up to one third. In fact, morphologic criteria are vague and highly subjective and the histologic diagnosis, therefore, remains highly controversial and unsatisfactory. New oligodendrocytic lineage markers, such as OLIG1/2 gene, will probably help to define the real spectrum of oligodendroglial tumors, which may include a wide variety of tumors with very different prognoses. Recently, genetic markers, and particularly loss of 1p and 19q chromosomes, have been shown to predict both prognosis and response to treatment. There is little doubt that these emerging techniques will be very helpful in clinical practice for refining both classification and therapeutic indications of oligodendroglial tumors.